SCHEMBL13633892

SCHEMBL13633892

Cc1nc(-c2ccsc2)oc1C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.50
KDM4E B2RXH2 1/20 0.41
CYP2A6 P11509 4/20 0.40
PPARA Q07869 3/20 0.39
PPARG P37231 2/20 0.39
TDO2 P48775 1/20 0.39
PDGFRB P09619 3/20 0.38
PDGFRA P16234 3/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
CYP2E1 P05181 1/20 0.36
CYP2B6 P20813 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
AR P10275 1/20 0.36
NPC1 O15118 1/20 0.36
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633872 0.80 PPARA (0.48) IKBKBKDM4ECYP2A6PPARAPPARG
SCHEMBL12163729 0.78 PPARA (0.45) IKBKBKDM4ECYP2A6PPARAPPARG
SCHEMBL13633790 0.75 TP53 (0.50) KDM4ENPC1
SCHEMBL436384 0.72 GAA (0.57) IKBKBKDM4ENPC1
SCHEMBL2706143 0.72 NPC1 (0.52) IKBKBKDM4ENPC1
SCHEMBL8360135 0.72 POLB (0.42) IKBKBKDM4ECYP2A6PPARATDO2
SCHEMBL2662367 0.70 ACHE (0.53) IKBKBCYP2A6PPARATDO2CA12
SCHEMBL5534902 0.69 KDM4E (0.59) IKBKBKDM4ENPC1
SCHEMBL14431592 0.69 GAA (0.54) KDM4ENPC1
SCHEMBL9862893 0.69 NPC1 (0.51) KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 IKBKB 585/4885KDM4E 4107/4885CYP2A6 263/4885
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 IKBKB 1392/4885KDM4E 4614/4885CYP2A6 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.